Traya is a haircare service provider that helps users identify the type, stage and root causes of hair loss and then tailors treatment plans accordingly. It assigns a life-sciences doctor and a dermatologist to each case to track, adjust and create the most appropriate plan. The company announced a $9 million strategic investment led by private equity fund Xponentia Capital. After the deal the brand's cumulative financing totaled $12 million, according to IT桔子. The funding announcement was published on April 3, 2024. Traya offers a proprietary hair diagnosis (Dx) that predicts time to see results and flags cases unlikely to improve, and delivers personalized plans combining topical products, nutrition, lifestyle coaching and medical consultation. The company says its Dx has enabled a 93% efficacy rate and offers a five‑month money‑back guarantee for hair‑loss treatment. On average, customers on Traya's recommended plan notice hair growth changes in five months. Traya positions itself as addressing hair loss as a medical issue rather than a cosmetic one, emphasizing multi‑disciplinary care rather than only topical solutions. The founders and investors frame the model as a potential disruptor with scope to scale beyond the current market. Traya.health (formerly Tatva Health) offers doctor-backed, personalised hair-loss solutions delivered to users at the tap of a finger, combining Ayurveda, allopathy, and nutrition to create comprehensive treatment plans. The company was founded by Saloni Anand, a techie-turned-marketeer, and Altaf Saiyed, a Stanford Business School alumnus. Traya positions itself as a service-focused healthtech product rather than a consumer shampoo brand, working closely with customers for long-term results. It plans to focus on hair loss this year and then expand into other lifestyle health problems affecting millennials. The startup says it will use its recently closed seed round to fund research and development, expand its product range, run detailed clinical trials, and build a technology-enabled adherence programme. The articles do not disclose revenue or user metrics.

Total raised

$11M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2024